Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Sept. 16, 2025 /CNW/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August 2025[1] signaled the recent wave of regulatory momentum behind next-generation therapies. Meanwhile, advanced treatment platforms are achieving complete tumor elimination in clinical trials across multiple cancer types[2]. These developments position Oncolytics Biotech Inc. (NASDAQ:ONCY), Anixa Biosciences, Inc. (NASDAQ:ANIX), IceCure Medical Ltd. (NASDAQ:ICCM), ImmunityBio, Inc. (NASDAQ:IBRX), and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Read more at newswire.caThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)